Surmodics, Inc. (NASDAQ:SRDX) Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System boosted its position in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 5,005.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,999 shares of the company's stock after purchasing an additional 50,000 shares during the period. California State Teachers Retirement System owned about 0.36% of Surmodics worth $2,020,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Legal & General Group Plc lifted its stake in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after purchasing an additional 880 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Surmodics during the 4th quarter worth approximately $217,000. Polymer Capital Management US LLC acquired a new position in shares of Surmodics in the 4th quarter valued at approximately $255,000. DeepCurrents Investment Group LLC acquired a new position in shares of Surmodics in the 4th quarter valued at approximately $260,000. Finally, Lighthouse Investment Partners LLC acquired a new position in shares of Surmodics in the 4th quarter valued at approximately $262,000. 96.63% of the stock is owned by hedge funds and other institutional investors.

Surmodics Stock Performance

Shares of NASDAQ SRDX traded down $0.21 during trading on Wednesday, reaching $28.99. The stock had a trading volume of 48,727 shares, compared to its average volume of 249,636. Surmodics, Inc. has a one year low of $26.00 and a one year high of $42.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The stock has a market cap of $414.53 million, a PE ratio of -28.70 and a beta of 1.33. The firm's 50 day moving average price is $28.55 and its two-hundred day moving average price is $33.04.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The company had revenue of $28.09 million for the quarter, compared to the consensus estimate of $32.23 million. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. On average, research analysts forecast that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SRDX. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a report on Friday, March 7th.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).